Background. While dysmetabolism is common in patients with chronic kidney disease (CKD) and associated with mortality, the mechanisms mediating these changes are unclear. New data implicate fibroblast growth factor (FGF)-19 as a possible entero-hepatic modulator of lipid metabolism. Methods. Using samples previously gathered as part of a randomized placebo-controlled study of antioxidative therapy for postprandial dysmetabolism, we investigated short-term (4 h) postprandial changes in circulating FGF-19 (ELISA) and the relationship to metabolic markers in six haemodialysis (HD) patients and nine matched healthy subjects (HS), with each participant assessed on four separate occasions. Results. The postprandial FGF-19 response was blunted in patients [maximum change +34.63 (0.24-186) pg/mL] versus controls [maximum change +150.3 (31.2-378.7) pg/mL; P < 0.0001], and the area under the curve (AUC; pg × min × mL
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Background. While dysmetabolism is common in patients with chronic kidney disease (CKD) and associated with mortality, the mechanisms mediating these changes are unclear. New data implicate fibroblast growth factor (FGF)-19 as a possible entero-hepatic modulator of lipid metabolism. Methods. Using samples previously gathered as part of a randomized placebo-controlled study of antioxidative therapy for postprandial dysmetabolism, we investigated short-term (4 h) postprandial changes in circulating FGF-19 (ELISA) and the relationship to metabolic markers in six haemodialysis (HD) patients and nine matched healthy subjects (HS), with each participant assessed on four separate occasions. Results. The postprandial FGF-19 response was blunted in patients [maximum change +34.63 (0.24-186) pg/mL] versus controls [maximum change +150.3 (31.2-378.7) pg/mL; P < 0.0001], and the area under the curve (AUC; pg × min × mL −1 ) was also significantly lower 18 019 (12 513-44 387) versus 38 517 (19 775-72 816; P < 0.01). In patients, we found univariate correlations between AUC FGF-19 with AUC C-peptide (rho = 0.71; P = 0.001), AUC insulin (rho = 0.63; P = 0.001), but not with AUCs for triglycerides (TG) or glucose. Finally, treatment with the antioxidative compounds N-acetyl cysteine or MP865, but not with placebo, was associated with higher plasma FGF-19 (NAC and MP865 coefficients −0.28 and −0.23, P < 0.05, respectively).
Conclusion.
In advanced CKD, the postprandial FGF-19 response appears to be blunted, with partial normalization following antioxidative treatments. A blunted FGF-19 response was associated with impaired insulin and C-peptide signalling.
I N T RO D U C T I O N
Most cytokines and peptide hormones are elevated in chronic kidney disease (CKD) [1] , likely due to impaired tubular uptake and metabolism [2] . Recently, fibroblast growth factor (FGF)-19, an enterokine synthesized and released when bile acids are taken up in the ileum, has been reported to activate a physiologically important, insulin-independent endocrine pathway that regulates protein and glycogen metabolism [3] . As CKD is a state of marked idiopathic dysmetabolism [4, 5] along with elevated levels of other enterokines, such as somatostatin [6] and ghrelin [7] , we performed the present study to better understand putative links between time-dependent stimulated FGF-19 release and nutrient homoeostasis in the uraemic milieu.
We used samples obtained during a previous study [8] , designed to investigate the impact of an energy-and fat-rich meal on postprandial oxidative stress and inflammation in patients with stage 5 CKD. This earlier study followed a randomized, double-blind design to assess the degree of postprandial oxidative stress and inflammation in patients versus healthy subjects (HS), as well as the ability of two putative antioxidant compounds (N-acetyl cysteine, NAC and MP865, essentially freeze-dried blueberries) to attenuate this response when compared with placebo (lactose).
M AT E R I A L S A N D M E T H O D S

Subjects
Ten prevalent non-diabetic CKD patients with maintenance haemodialysis (HD) for at least 3 months, and treated for at least three times per week and 3.5 h per treatment using biocompatible membranes, were enrolled. We also recruited 10 unrelated non-diabetic HS to serve as a control group. Exclusion criteria for both groups were age under 20 or over 70 years, ongoing treatment for infection or inflammatory disease, mental illness, chronic bowel disease, a history of cholecystectomy and/or malabsorption and known liver disease. The study was approved by the Ethical Review Board of the Karolinska institute prior to recruitment, and all participants gave written informed consent. Each individual was assessed four times, with 7 days between each assessment. daily) in random order for 7 days, with a further 7 days washout period between treatments. Each participant was repeatedly assessed following 7 days treatment and an overnight fast of at least 8 h, with each assessment consisting of a standardized high fat, carbohydrate-rich meal followed by 4 h of repeated blood sampling. The study design is illustrated in Figure 1 .
Standardized meal provocation
Following an overnight fast of at least 8 h, patients and HS were sampled (on the day after a dialysis session in the case of patients). A dietitian-designed meal consisting of 75 g of milk fat, 5 g of carbohydrates and 6 g of proteins/m 2 of the body surface area (corresponding to a total caloric intake of 700 kcal/m 2 of the body surface area) was administered during 10 min as a milkshake, immediately followed by 75 g of glucose mixed with 500 mL of purified water during 5 min. The meal was designed to mimic a heavy dinner in calories and nutrient composition [8] .
Sampling protocol
Venous blood samples were collected at 30, 60, 120, 180 and 240 min after meal intake in both HS and patients. Each participant was sampled using the above protocol. Plasma and serum were extracted immediately and subsequently frozen at −80°C until analysis.
Biochemical assays
Plasma levels of FGF-19 were measured by an enzymelinked immunosorbent assay (ELISA; Human FGF19 Quantikine ELISA kit, cat. no. DF1900, R&D Systems, Minneapolis, MN, USA-monoclonal antibody specific for FGF-19) and according to the manufacturer's instructions. Serum concentrations of C-peptide, insulin, interleukin (IL)-6 and tumour necrosis factor (TNF)-α were determined using an Immulite Automatic Analyzer (Siemens Medical Solutions Diagnostic Products, Los Angeles, CA, USA). Serum glucose and triglycerides were measured using routine methods at the Department of Laboratory Medicine, Karolinska University Hospital. The levels of advanced oxidation protein products (AOPPs) was measured using the modified assay (mAOPP) by our group, original assay and following precipitation of plasma lipids using dextran sulphate [9] .
Body mass index and insulin resistance The body mass index (BMI) was calculated as weight (kg)/ (height [m])
2 . The homoeostasis model assessment of insulin resistance (HOMA-IR) and early phase insulin secretion (insulinogenic index) were calculated as described [10] .
Statistical methods
During the study, four patients and one control droppedout. Data from these were excluded from analysis, and the final cohort thus consisted of six patients and nine HS. Results for normally distributed variables are expressed as means ± standard deviation or standard error of the mean. For nonnormally distributed variables, median and inter-quartile (10-90 percentiles) are shown instead. A statistical significance was set at P < 0.05. P-values were not adjusted for multiple testing.
The original study design. A randomized placebo-controlled study of the effect of two antioxidative treatments on blood biochemical markers of postprandial oxidative damage.
We used AUC over time to assess totals. The AUC for 0-240 min was calculated by the trapezoidal method. To compare AUCs between groups, we used a non-parametric Wilcoxon signed-rank test.
A mixed-effect statistical model was used to account for intra-individual variations due to repeated observations of plasma FGF-19, mAOPP and triglycerides. The fixed effects of the model included age, sex, group (healthy subject and patient), treatments and time points. We also calculated the intraclass correlation (ICC) from estimates of between-subject and within-subject variance. The ICC quantifies the percentage of the total variation explained by variation between-subjects. A high ICC indicates that most of the observed variability over repeat measurements is explained by between-subject variations, thus implying that the individual variation is low.
All statistical analyses was performed using the statistical software SAS version 9.3 (SAS Campus Drive, Cary, NC, USA 27513).
R E S U LT S
Baseline clinical characteristics
Baseline clinical features and measured biochemical parameters from studied subjects are shown in (Table 1) . Briefly, the HS and patients were well matched with regard to age, sex and BMI. Median fasting FGF-19 levels were 126.6 (63.9-216) pg/mL in HS and 84.3 (67-158.6) pg/mL in patients.
Univariate correlations
Univariate correlations between AUC values of biochemical variables across the four study sessions were calculated for patients and HS together (Table 2 ) and separately (below). Briefly, in HS, AUC C-peptide correlated with AUC glucose (rho = 0.76, P = 0.001), AUC insulin (rho = 0.83, P = 0.001) and AUC TNF-α (rho = 0.42, P = 0.01). Also in HS, AUC TNF-α correlated with AUC TG (rho = 0.36, P = 0.03) and AUC insulin (rho = 0.56, P < 0.001), while AUC glucose was correlated with AUC insulin (rho = 0.67, P < 0.001). AUC FGF-19 in HS correlated only with AUC IL-6 (rho = −0.38, P = 0.02), while none of the other measured AUC showed significant correlation.
In patients, AUC C-peptide correlated with AUC TNF-α (rho = −0.48, P = 0.04), AUC IL-6 correlated with AUC TG (rho = −0.64, P = 0.001), whereas AUC FGF-19 correlated with both AUC insulin (rho = 0.63, P = 0.001) and AUC Cpeptide (rho = 0.71, P = 0.001).
Univariate correlations between maximum changes in FGF-19, with selected biochemical variables across the four study sessions were calculated for HS and patients separately ( Figure 2A-C) . Briefly, in HS, there were no significant correlations. In patients, maximum change in FGF-19 correlated with maximum change in plasma glucose (rho = 0.47, P = 0.02); the maximum change in glucose also correlated with maximum change in mAOPP (rho = 0.54, P = 0.04) and triglycerides (rho = −0.43, P = 0.04) (data not shown).
Multivariate regression analysis
We performed multivariate mixed models, which included age, sex, treatments, groups (HS versus patients) and time points. Using FGF-19 levels as the outcome variable, the mixed model (Table 3; Thus, the postprandial FGF-19 response was markedly blunted in patients ( Figure 3A) . In a mixed model using mAOPP as the dependent variable, our model (Table 4 ; ICC = 0.26, SE = 0.09) intercept coefficient was 6.24 (SE = 0.19, P < 0.01) with significant predictors being age (−0.008, SE = 0.003; P = 0.01), group (1.23, SE = 0.06; P < 0.01) and time point (0 min versus 180 min: −0.12, SE = 0.03, P < 0.01; 0 min versus 240 min: −0.09, SE = 0.03, P < 0.01). Measured baseline mAOPP levels were high in comparison with HS, and did not show statistically significant variation the study ( Figure 3B) . Bold values mark statistical significance (P < 0.05). The ICC value for FGF-19 was lower (more stable over time) than those for mAOPP and glucose. Implied withinsubject associations were 79, 74 and 65%, respectively (Figure 4 ).
D I S C U S S I O N
Using data and samples generated during an earlier randomized, controlled clinical trial [8] designed to assess the impact of antioxidative therapy on postprandial inflammation; we assess the postprandial response in FGF-19 in a small group of HS and patients with end-stage CKD receiving maintenance HD. Our results demonstrate a markedly blunted response in plasma FGF-19 response in HD patients, while therapy with either of the antioxidants NAC or freeze-dried blueberries was able to attenuate, but not completely normalize, the response in the same patients (Supplementary data, Figures S1 and S2) .
While the postprandial metabolic response in CKD is known to be characterized by hyperinsulinaemia and elevated Correlation between treatments and time points and group (healthy subject and patients) adjusted for age and gender.
F I G U R E 3 : (A) Changes in postprandial FGF-19 levels over time in six patients (black) and nine healthy subjects (white) with four treatments. (B) Changes in postprandial mAOPP levels over time in six patients (black) and nine healthy subjects (white) with four treatments (aggregated data from four treatment-series after first checking for differences between treatments).
apo-lipoprotein B containing cholesterol [11, 12] , ours is the first study to demonstrate a blunted response of a regulating protein linked to dysmetabolism that is partially reversible following therapy. Reiche et al. [13] in a cross-sectional study of 60 fasting chronic HD patients and 60 controls recently demonstrated that serum FGF-19 levels may be, on average, 1.5 times higher in patients, as well as correlate negatively with inflammation. The measured signalling protein FGF-19 (also called FGF-15 in rodents) is a member of a subfamily of which several members have been demonstrated to have metabolic activity. These include FGF-21, which has been shown to regulate hepatic lipid and glucose metabolism [14] and FGF-23, which is much studied in CKD as a regulator of phosphate metabolism, but has also been suggested to influence mineral ion metabolism [15] including in CKD patients [16] . In man, FGF-19 has been suggested to act as an ileum-derived enterokine for feedback regulation of hepatic synthesis of bile acids [17] . After a meal, bile acids released into the intestines stimulate the expression of FGF-19 which in turn circulates through the blood to receptors in the liver [17, 18] . Thus, a blunted FGF-19 response following a meal such as the one we observed may signify either decreased enteric function and/or sensitivity, perhaps due to wall oedema, as well as an impaired entero-hepatic transport of gall. Surprisingly, compared with Reiche et al. [13] , we saw plasma levels of FGF-19 that at baseline were 250% times lower in patients and 30% lower in controls. These differences may be from the use of different immunoassays run on different sample matrixes (serum versus plasma), or they may derive from some as yet unknown physiological process. Treatment for 7 days with either NAC or MP485, essentially freeze-dried blueberries containing natural anthocyanidins [19] , was independently associated with an increase in postprandial FGF-19 levels without changing fasting FGF-19 levels.
Why antioxidative therapy should increase plasma FGF-19 in patients with CKD is unclear. Our data on mAOPP indicate that the studied patients suffered from relatively extensive oxidative protein damage, suggesting high oxidative stress. Indeed, kidney disease is thought to be associated with increased oxidant production [20, 21] , as well as decreased antioxidant capacity [22] , while NAC has previously been reported to have beneficial metabolic effects in patients with CKD [23] while also being widely, if somewhat unscientifically, used to prevent contrast nephropathy following radiological procedures [24] . Here, we saw a response comparable with NAC also when using MP865. Both NAC and anthocyanidins are known to scavenge oxygen radicals, but both also exhibit unspecific cellular effects, as may be imagined from their small, non-specific size and molecular configuration. Anthocyanidines have in vitro shown an ability to reduce insulin resistance in cultured adipocyte-like cells provoked with superoxide [25] , while NAC, besides acting as an NO carrier in vivo [26] , is thought to regulate the redox-sensitive JNK1/2 and 
Variance components for FGF-19, mAOPP and glucose in HD. The intraclass correlation (ICC) was calculated from estimates of between-subjects and within-subject derived from mixed models.
p38 stress kinases [27] along with the transcription factor Nrf2 [28] , thereby hypothetically also modifying insulin signalling pathways [29] [30] [31] . Clearly, the current study design did not allow us to investigate which, if any, of these reported functions of the two compounds played a role in modifying immunoreactive plasma FGF-19.
In the interpretation of our results, several limitations should be noted. First, the small samples size of the study. Secondly, as mentioned, dysfunction of the gallbladder leading to bile secretion beyond the 4 h sampling period could also explain the low FGF-19 responses. Finally, confounding by unmeasured factors cannot be ruled out in this observational study.
In summary, in a small study of CKD patients undergoing HD, we demonstrate differences in postprandial plasma FGF-19 compared with HS. We did not observe the hypothesized increase in the oxidative stress marker mAOPP following a meal.
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